Respiratory Research

Table 2 Change from baseline in trough FEV₁ (litres) (last observation carried forward) at week 8, by evening (PM) vs. morning (AM) FEV₁ and treatment group (ITT population)

From: Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

Week 8 PM FEV₁
	Placebo (n = 101)	FF dose
		200 mcg OD/PM ( n = 103)	400 mcg OD/PM ( n = 113)	200 mcg BD ( n = 113)
Trough FEV₁ (n)	77	92	103	100
LS mean (SE)	2.198 (0.0458)	2.322 (0.0437)	2.438 (0.0398)	2.432 (0.0411)
LS mean change (SE)	0.084 (0.0458)	0.208 (0.0437)	0.324 (0.0398)	0.319 (0.0411)
Difference from placebo
Difference		0.124	0.240	0.235
95% CI		0.010, 0.238	0.129, 0.351	0.123, 0.346
p value		0.033	< 0.001	< 0.001
Week 8 AM FEV ₁
	Placebo ( n = 101)	FF dose
		200 mcg OD/AM ( n = 105)	400 mcg OD/AM ( n = 111)	200 mcg BD ( n = 113)
Trough FEV₁ (n)	85	100	106	102
LS mean (SE)	2.029 (0.0434)	2.203 (0.0389)	2.230 (0.0397)	2.344 (0.0400)
LS mean change (SE)	0.053 (0.0434)	0.228 (0.0389)	0.255 (0.0397)	0.368 (0.040)
Difference from placebo
Difference		0.174	0.202	0.315
95% CI		0.067, 0.282	0.096, 0.307	0.208, 0.421
p value		0.002	< 0.001	< 0.001

BD = twice daily; CI = confidence interval; FEV₁ = forced expiratory volume in one second; FF = fluticasone furoate; LS = least square; OD = once daily; SE = standard error

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com